Clinical Trial

Metabolic and Epigenetic Impact of FAAH Inhibitors and OEA

Completed
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn whether a dietary supplement can affect gene expression and serum protein markers in healthy volunteers. The main questions it aims to answer are: 1. Does the supplement affect gene expression and protein markers as measured in blood? 2. How does daily ingestion of the supplement affect anthropometric measurements, including body mass index, waist circumference, blood pressure, and heart rate? 3. How does daily ingestion of the supplement affect subjective health parameters? 4. Is ingesting the supplement daily safe, as measured by laboratory tests and adverse events? The supplement is made with oleoylethanolamide (OEA), ginger extract, and lavender essential oil. Participants will: * Take one supplement capsule in the morning and one in the evening every day for 12 weeks * Attend three study visits in which they provide blood and urine samples, and undergo anthropometric measurements * Complete surveys and subjective health assessments
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-11; most recent amendment 2026-03-09.
Status change: Recruiting → Completed 2026-03-09
Status change: Not Yet Recruiting → Recruiting 2025-08-21
Trial Details
NCT Number NCT07127445
Lead Sponsor Nicole Stevens, PhD
Conditions Healthy
Enrollment 92 participants
Start Date 2025-08-19
Primary Completion 2025-12-19 (estimated)
Study Completion 2025-12-19 (estimated)
Updated on ClinicalTrials.gov 2026-03-10